

**STEPHEN D. NIMER, M.D.**  
Curriculum Vitae

Date: 6/12/2015

PERSONAL

Name: Stephen David Nimer

Office Phone: (305) 243-1775

Current Academic Rank: Professor

Primary Department: Medicine

Secondary or Joint Appointments: Biochemistry and Molecular Biology

HIGHER EDUCATION

Institutional (institution; degree; date conferred):  
Massachusetts Institute of Technology, Cambridge MA  
B.S. Biology, February 1975

Univ. of Chicago (Pritzker) School of Medicine, Chicago IL  
M.D. with Honors, June 1979

Certification, licensure (description; board or agency; dates):

BOARD CERTIFICATION:

September 1982	American Board of Internal Medicine
November 1985	Board Certified Medical Oncology
November 1986	Board Certified Hematology

MEDICAL LICENSE:

State of California:	1979-present
State of New York:	1993-present
State of Florida:	2012-present

EXPERIENCE

Academic (institutions; rank/status; dates):

5/2012 – Present:	Professor of Medicine, Biochemistry & Molecular Biology, University of Miami Miller School of Medicine
7/2005 – Present:	Professor of Pharmacology, Weill Medical Coll. of Cornell University
4/2013 – Present:	Consulting Medical Staff, The Rockefeller University Hospital

9/2004 – 12/2013: Professor, Gerstner Sloan-Kettering Graduate School  
9/2006 – 4/2013: Visiting Physician, The Rockefeller University Hospital  
7/2000 – 12/2011: Professor of Medicine, Weill Medical College of Cornell University  
1/1993 – 12/2000: Associate Professor of Medicine  
Cornell Univ. Medical College, New York, NY  
7/1987- 12/1992: Assistant Professor of Medicine  
Division of Hematology-Oncology  
UCLA School of Medicine, Los Angeles, CA  
1/1992- 12/1992: Co-Director, Internal Medicine Residency Training Program,  
UCLA School of Medicine, Los Angeles, CA  
UCLA School of Medicine, Los Angeles, CA  
1/1990- 12/1992: Associate Director, Fellowship Program  
Division of Hematology/Oncology  
UCLA School of Medicine, Los Angeles, CA  
7/1986-7/1987: Adjunct Instructor of Medicine  
Department of Medicine  
UCLA School of Medicine, Los Angeles, CA  
1979: Teaching Assistantship  
Univ. of Chicago Medical School Chicago, IL

Non-Academic (employers; title; responsibilities; dates):

2012 – Present: Director, Sylvester Comprehensive Cancer Center  
2008 – 5/2012: Alfred P. Sloan Chair in Cancer Research  
2008 – 5/2012: Vice Chair, Faculty Development, Department of Medicine, MSKCC  
5/2012-Present: Visiting Investigator, Memorial Sloan-Kettering Institute for Cancer Research  
1999 – 5/2012 Member, Sloan-Kettering Institute for Cancer Research  
1999 – 5/2012 Member, Memorial Sloan-Kettering Cancer Center  
7/1999 - 5/2012 Attending Physician, Memorial Hospital  
2001- 2006 Attending Physician, Cytogenetics Service, MSKCC  
1996- 2008 Head, Division of Hematologic Oncology  
Memorial Sloan-Kettering Cancer Center, NY, NY  
1/1993- 6/2010 Chief, Hematology Service, MSKCC  
1/1993- 6/1999 Associate Attending Physician  
Memorial Hospital, New York, NY  
1/1993- 6/1999 Associate Member, Memorial Hospital  
1/1993- 6/1999 Associate Member, Sloan-Kettering Institute for Cancer Research  
1991- 1992 Acting Director, Bone Marrow Transplant Unit  
1990- 1991 Associate Director, Bone Marrow Transplant Unit  
UCLA School of Medicine, Los Angeles, CA  
10/1991-12/1992 Director, Transplantation Biology Program  
1990-1991 Co-Director, Transplantation Biology Program  
Jonsson Comprehensive Cancer Center  
UCLA School of Medicine, Los Angeles, CA

## PUBLICATIONS

### BOOKS AND MONOGRAPHS:

Nimer SD, Golde DW, eds. Hematologic Complications of Cancer. Philadelphia, PA: W.B. Saunders, 1996.

Juried or refereed journal articles and exhibitions:

### PEER-REVIEWED PAPERS:

1. Liu F, Cheng G, Hamard PJ, Greenblatt S, Wang L, Man N, Perna F, Xu H, Tadi M, Luciani L, Nimer SD. PRMT5 is essential for sustaining adult hematopoietic stem and progenitor cells. *Journal of Clinical Investigation* 2015 May *In press*.
2. Wang L, Man N, Sun XJ, Tan Y, Cao M, Liu F, Hatlen M, Xu H, Huang G, Mattlin M, Mehta A, Rampersaud E, Benezra R and Nimer S. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression *Blood* 2015 May *In press*
3. Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T. Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis. *Br J Haematol.* 2015 May *In press*
4. Perna F, Vu L, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine R, Studer L, Sadelain M, Nimer SD. The Polycomb group protein L3MBTL1 represses a SMAD5-mediated transcriptional program in human pluripotent stem cells. *Stem Cell Reports.* 2015, 4(4): 658-69
5. Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine RL. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. *Cancer Cell.* 2015 Apr 13; 27(4):502-15
6. Kotini AG, Chang C, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally A, Perna F, Fishbein GA, Klimek VM, Hawkins DR, Huangfu D, Murry CE, Graubert T, Nimer SD, Papapetrou EP. Functional dissection of hemizygous chromosomal deletions with human induced pluripotent stem cell models of myelodysplastic syndromes. *Nature Biotechnology.* 2015, 33(6): 646-55
7. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. *Cell Rep.* 2014, 9(5):1841-55
8. List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. *Leukemia.* 2014, 28:1033-1040.
9. Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W Julloy JC, Nimer SD, Huang G. Down-regulation of RUNX1/CBF $\beta$  by MLL fusion proteins enhances HSC self-renewal. *Blood.* 2014, 123(11) 1729-38.
10. Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD. PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex. *Cell Reports*

2013, 5(6): 1625-38

11. Sun SJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, Fischie W, Melnick A, Patel DJ, Nimer SD, Roeder RG. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. *Nature*. 2013, 500:93-7.
12. Altman JK, Rademaker A, Cull E, Weitner B, Ofran Y, Rosenblat T, Haidau A, Park J, Ram S, Orsini Jr. J, Sandhu S, Catchatourian R, Trifilio S, Adel N, Frankfurt O, Stein E, Mallios G, Deblasio T, Jurcic J, Nimer S, Peter L, Kwaan H, Rowe J, Douer D, Tallman M. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. *Leuk Res* 2013, 37(9): 1004-9
13. Ando K, Tsushima H, Matsuo E, Horio K, Tominaga-Sato S, Imanishi D, Imaizumi Y, Iwanaga M, Itonaga H, Yoshida S, Hata T, Moriuchi R, Kiyoi H, Nimer S, Mano H, Naoe T, Tomonaga M, Miyazaki Y. Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformation. *J Biol Chem*. 2013; 288:9457-67.
14. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. *Haematologica*. 2013; 98:908-12
15. Bazzoli E, Pulvirenti T, Oberstadt MC, Perna F, Wee B, Schultz N, Huse JT, Fomchenko EI, Voza F, Tabar V, Brennan CW, DeAngelis LM, Nimer SD, Holland EC, Squatrito M. MEF promotes stemness in the pathogenesis of gliomas. *Cell Stem Cell*. 2012; 11:836-44.
16. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. *Cancer Cell*. 2012;22:683-97.
17. Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, Mellinghoff IK, Rosen N, Pandolfi PP, Hedvat CV, Nimer SD. Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. *Sci Signal* 2012; 5(247): ra77.
18. Xu H, Menendez S, Schlegelberger B, Bae N, Aplan PD, Gohring G, Deblasio TR, Nimer SD. Loss of p53 accelerates the complication of myelodysplastic syndrome (MDS) in a NUP98-HOXD13 driven mouse model. *Blood* 2012;120:3089-97.
19. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Alfantis I, Bernstein BE, Levine, RL. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene expression. *Cancer Cell* 2012;22:180-93.
20. Koppikar P, Bhagwat N, Kilpivaara O, Manshour T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gonen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. *Nature* 2012; 489(7414):155-9.
21. Asai T, Liu Y, Di Giandomenico S, Bae N, Ndiaye-Lobry D, Deblasio A, Menendez S, Antipin Y, Reva B, Wevrick R, Nimer SD. Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. *Blood* 2012; 120(8):1601-12.
22. Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD,

- Schwartz GK. The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy Induces Apoptosis of p53 Mutated Multiple Myeloma Cells. *Mol Cancer Ther.* 2012; 11(8):1781-8.
23. Klimek VM, Dolezal EK, Tees MT, Devlin SM, Stein K, Romero A, Nimer SD, Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. *Leuk Res.* 2012; 36(9):1093-7.
  24. Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, Matsuura S, Komeno Y, Zhao X, Nimer SD, Yates JR 3rd, Zhang DE. PRMT1 interacts with AML1- ETO to promote its transcriptional activation and progenitor cell proliferative potential. *Blood.* 2012;119:4953-62.
  25. Dawson MA, Bannister AJ, Saunders L, Wahab OA, Liu F, Nimer SD, Levine RL, Gottgens B, Kouzarides T, Green AR. Nuclear JAK2. *Blood.* 2011;118:6987-8.
  26. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horowitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schroder H, Yahalom J. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood.* 2012;119:1665-70.
  27. Klimek VM, Dolezal EK, Smith L, Soff G, Nimer SD. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia. *Leukemia Research.* 2011;36:570-4.
  28. Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu, Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JD, Nimer S. The ability of MLL to bind RUNX1 and methylate H2K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. *Blood.* 2011;118:6544-52.
  29. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen M, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Mendenz S, Voza F, Jiang Y, Cole P, Zhang J, Melnick A, Roeder R, Nimer SD. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. *Science.* 2011;333:765-9.
  30. Moulick M, Ahn JH, Cerchietti L, Beebe K, Smith-Jones P, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Rodina A, Alpaugh M, Gross SS, Larson SM, Levine R, Guzman M, Erdjument-Bromage H, Nimer SD, Melnick A, Neckers L, Chiosis G. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nature Chemical Biology.* 2011;7:818-26.
  31. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick R, Godley LA, Aifantis I, Levine R. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell.* 2011;20:11-24.
  32. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, Harr MW, Levine RL, Xu H, Tefferi A, Deblasio A, Hatlen M, Menendez S, Nimer SD. JAK2V617F-mediated phosphorylation of PRMT5 down-regulates its methyltransferase activity and promotes myeloproliferation. *Cancer Cell.* 2011;19:283-94.
  33. Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N, Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer SD. The Mef/Elf4 transcription factor fine tunes the DNA damage response. *Cancer Research.* 2011;71:4857-65.
  34. Hoya-Arias R, Tomishima M, Voza F, Nimer SD. L3MBTL1 deficiency directs the differentiation of human embryonic stem cells towards trophectoderm. *Stem Cells and Development.* 2011;20:1889-1900.
  35. Gurvich N, Perna F, Farina A, Voza F, Menendez S, Hurwitz J, Nimer SD. The L3MBTL1 Polycomb Protein, a Candidate Tumor Suppressor in del(20q12) Myeloid Disorders, is Essential for Genome Stability. *PNAS.* 2010;107:22552-57.

36. Perna F, Abdel-Wahab O, Levine LR, Jhanwar CJ, Imada K and Nimer SD ETV6-ABL-positive “CML”: clinical and molecular response to tyrosine kinase inhibition with imatinib. *Haematologica* 2010; 96:342-3.
37. Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutriex C, Huntsman-Labed A, Virkus J, Giles FJ. Phase IIB Trial of oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia and High- Risk Myelodysplastic Syndrome With Either Wild- Type or Mutated FLT3. *J Clin Oncol.* 2010; 28: 4339-45.
38. Perna F, Gurvich N, Hoya-Arias R, Abdel-Wahab O, Levine RL, Asai T, Voza F, Wang L, Liu F, Zhao X, Nimer SD. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. *Blood.* 2010;116:2812-2821.
39. Moskowitz C, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice R, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O’Connor OA, Portlock C, Straus D & Nimer SD. High-Dose Chemo-Radiotherapy for Relapsed or Refractory Hodgkin Lymphoma and the Significance of Pre-transplant Functional Imaging. *Br. J. Haem.* 2010;148:890-7.
40. Mathew S, Adel N, Rice R, Panageas K, Duck E, Comenzo R, Kewalramani T & Nimer SD. Retrospective Comparison of Filgrastim and Pegfilgrastim on the Pace of Engraftment in Autologous Stem Cell Transplant Patients. *BMT.* 2010;45:1522-7.
41. Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M & Nimer SD. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. *Stem Cells.* 2010;28:3008-17.
42. Gao J., Graves S., Koch U., Liu S., Jankovic V., Buonamici S., El Andaloussi A., Nimer SD., Kee BL., Taichman R., Radtke F., Aifantis I. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. *Cell Stem Cell* 2009;4:548-58.
43. Sashida G, Liu Y, Elf S, Miyata Y, Ohyashiki K, Izumi M, Menendez S, & Nimer SD. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. *Mol Cell Biol.* 2009;13:3687-99.
44. Lin HK, Wang G, Chen Z, Feldstein JT, Liu Y, Chan CH, Yang WL, Bromage HE, Nakayama KI, Nimer S, Tempst P & Pandolfi PP. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. *Nature Cell Biology.* 2009; 11:420-32.
45. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Deblasio A, Menendez S, Koff A & Nimer SD. p53 Regulates Hematopoietic Stem Cell Quiescence. *Cell Stem Cell.* 2009;4:37-48.
46. Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P; Plasma Cell Disorders Working Committee. Comparison of twin and autologous transplants for multiple myeloma *Biol. Blood Marrow Transplant.* 2008;14:1118-24.
47. Hassoun H, Flombaum C, D’Agati V, Rafferty B, Cohen A, Klimek V, Boruchov A, Kewalramani T, Reich L, Nimer S & Comenzo R. High-Dose Melphalan and High-dose melphalan and auto-SCT in Patients with Monoclonal Immunoglobulin Deposition Disease. *Bone Marrow Transplantation* 2008;42:405-12.
48. Kalakonda N, Fischle W, Bocconi P, Gurvich N, Hoya-Arias R, Zhao X, Miyata Y, Macgrogan D, Zhang J, Sims JK, Rice JC, Nimer SD. *Oncogene.* 2008 Jul 17;27(31):4293-304. doi: 10.1038/onc.2008.67. Epub 2008 Apr 14
49. Thompson B, Jankovic V, Gao J, Buonamici S, Vest A, Lee J, Zavadil J, Nimer S & Aifantis I.

- Control of hematopoietic stem cell quiescence by the E3 Ubiquitin Ligase Fbw7. *Journal of Experimental Medicine* 2008;205:1395-408.
50. Becker H, Pfeifer D, Afonso JD, Nimer SD, Veelken H, Schwabe M, Lübbert M, et al. Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis. *Leukemia* 2008;22:1792-4.
  51. Zhao X, Jankovic V, Gural A, Huang G, Pardanani A, Menendez S, Zhang J, Dunne R, Xiao A, Erdjument-Bromage H, Allis C, Tempst P & Nimer S. Methylation Of RUNX1 By PRMT1 Abrogates SIN3A binding and Potentiates its Transcriptional Activity. *Genes & Development* 2008; 22:640-53.
  52. Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW, Nimer SD, Boruchov AM. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. *Blood* 2008;111:3403-6. 135.
  53. Schlenk R, Pasquini M, Perez W, Zhang M, Krauter J, Antin J, Bashey A, Bolwell B, Buchner T, Cahn J, Cairo M, Copelan E, Cutler C, Dohner H, Gale R, Ilhan O, Lazarus H, Liesveld J, Litzow M., Marks D, Maziarz R, McCarthy P, Nimer S, Sierra J, & Tallman M. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in the first complete remission: collaborative study between the German AML Intergroup and CIBMTR. *Biology Blood Marrow Transplant.* 2008;14:187-96.
  54. Morales M, Liu Y, Laiakis E, Morgan W, Nimer S, & Petrini J. DNA damage signaling in hematopoietic cells: A role for Mre11 complex repair of topoisomerase lesions. *Cancer Research.* 2008;68:2186-93.
  55. Klimek V, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panaheas K, Wright J, Pandolfi P & Nimer S. Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes. *Clinical Cancer Research.* 2008;14:826-32.
  56. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. *Biology Blood Marrow Transplant.* 2008;14:458-68.
  57. Huang G, Zhang P, Hirai H, Elf S, Yan X, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Gowney J, Shivdasani R, Gilliland D, Speck N, Nimer S & Tenen D. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse. *Nature Genetics.* 2008;40:51-60. Epub 2007 Nov 11.
  58. Ciarrocchi A, Jankovic V, Shaked Y, Nolan D, Mittal V, Kerbel R, Nimer S & Benezra R. ID1 restrains p21 expression in the bone marrow to control endothelial progenitor cell formation. *PLOS One.* 2007;2:e1338.
  59. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa D, Riedel E, Kewalramani T, Stubblefield M, Fleisher M, Nimer S, Comenzo RL. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain (AL-) amyloidosis: results of a phase II trial. *British Journal of Haematology.* 2007;139:224-33.
  60. C.H. Moskowitz, P.A. Hamlin, J. Gabilove, J.R. Bertino, C. S. Portlock, D.J. Straus, A.N. Gencarelli, S.D. Nimer & A.D. Zelenetz. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. *Annals of Oncology.* 2007;18: 1842-50.
  61. Trojer P, Li G, Sims III RJ, Vaquero A, Kalakonda N, Boccuni P, Lee D, Erdjument-Bromage H, Tempst P, Nimer SD, Wang Y-H, Reinberg D. L3MBTL1, a histone methylation dependent chromatin lock. *Cell.* 2007;129:915-28.

62. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A, On behalf of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF) post polycythemia vera myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). *Leuk Res.* 2007;31:737-40.
63. Jankovic V, Ciarrocchi A, Boccuni P, DeBlasio T, Benezra R, Nimer SD. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. *Proc Natl Acad Sci USA.* 2007;104:1260-5.
64. Gu TL, Popova Lana, Reeves C, Nardone J, MacNeill J, Rush, J, Comb MJ, Nimer SD, Polakiewicz RD. Identification of the M0-91 cell line as a model for the study of TEL-TRKC fusion associated human cancers by phosphoproteomic analysis. *Leukemia.* 2007;21:563-6.
65. Yao J, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD, Hedvat, CV. Tumour promoting properties of the ETS protein MEF ovarian cancer in. *Oncogene.* 2007;26:4032-7.
66. Tuma RA, Almyroudis NG, Sohn SJ, Panageas K, Rice RD, Galinkin D, Blain M, Montefusco M, Pamer EG, Nimer SD, Kewalramani T. The serum IL-12:IL-6 ratio reliably distinguishes infectious from non-infectious causes of fever during autologous stem cell transplantation. *Cytotherapy.* 2006;8:327-334.
67. De Angelo D, Stone R, Heaney M, Nimer SD, Paquette R, Klisovic R, Caligiuri M, Cooper M, Lecerf JM, Karol M, Sheng S, Holford N, Curtin P, Druker B, Heinrich M. Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. *Blood.* 2006 ;108:3674-81
68. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, Dipersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer.* 2006;106:1794-1803.
69. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand dependent activation of human Natural Killer T cells by Lenalidomide: Therapeutic Implications. *Blood.* 2006;108:618-21.
70. Liu Y, Hedvat C, Mao S, Zhu X, Yao J, Nguyen H, Koff A, Nimer SD. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. *Mol Cell Biol.* 2006;26:3114-3123.
71. Lacorazza D, Yamada T, Liu Y, Miyata Y, Sivina M, Nunes J, Nimer SD. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. *Cancer Cell.* 2006; 9:175-187 (cover article).
72. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, deWitte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical Application and Proposal for Modification of the International Working Group (IWG) Response Criteria in Myelodysplasia. *Blood* 2006; 108: 419-25.
73. Pabst T, Stillner E, Neuberg D, Nimer SD, Willman CL, List AF, Melo JV, Tenen DG, Mueller BU. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukemia. *Br J Haematol.* 2006; 133: 40-2.
74. Abrey L, Childs B, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay J, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith A, Macdonald D, Weaver S, Ramsay D, Nimer S, DeAngelis L, Cairncross G. Anaplastic oligodendroglioma: Long-term



- Follow-up. *J. Neuro-Oncology*. 2006;8:183-188.
75. Abrey L, Childs B, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay J, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith A, Macdonald D, Weaver S, Ramsay D, Nimer S, DeAngelis L, Cairncross G. Anaplastic oligodendroglioma: Long-term Follow-up. *J. Neuro-Oncology*. 2006;8:183-188.
  76. Comenzo R, Hassoun H, Kewalramani T, Klimek V, Dhodapkar M, Reich L, Teruya-Feldstein J, Fleisher M, Filippa D, Nimer SD. Results of a phase I/II trial adding carmustine (300 mg/m<sup>2</sup>) to melphalan (200 mg/m<sup>2</sup>) in multiple myeloma patients undergoing autologous stem cell transplantation. *Leukemia*. 2006;20:345-349.
  77. Maslak P, Chanel S, Camacho LH, Soigner S, Pandolfi PP, Guernah I, Warrell R, Nimer S. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-Azacytidine in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). *Leukemia*. 2006;20:212-217.
  78. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede HM, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. *Blood*. 2006; 107:293-300.
  79. Lin YW, Deveney R, Barbara M, Iscove NN, Nimer SD, Slape C, Aplan PD. OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. *Cancer Res*. 2005;65:7151-7158.
  80. Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo R. Doxorubicin and dexamethasone followed thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. *Br. J. Haem.* 132:155-161 2006.
  81. Zhu H, Traver D, Davidson AJ, Dibiase A, Thisse C, Thisse B, Nimer S, Zon LI. Regulation of the Lmo2 promoter during hematopoietic and vascular development in zebrafish. *Dev Biol*. 2005;281:256-269.
  82. Mulloy JC, Jankovic V, R, Cammenga J, Krejci O, Zhao H, Valk PJM, Lowenberg B, Nimer SD. AML1-ETO upregulates TRKA expression in Wunderlich M, Delwel human CD34+ cells allowing NGF-induced expansion. *Proc. Natl. Acad. Sci USA*. 2005;102:4016-4021.
  83. Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. *BMT*. 2005; 35:441-447.
  84. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary C, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C and Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). *Blood*. 2005;105: 335-340.
  85. Moskowitz C, Zelenetz A, Kewalramani T, Hamlin P, Lessac-Chenen S, Houldsworth J, Olshen A, Chaganti R, Nimer S, Teruya-Feldstein J. Cell of Origin, Germinal Center versus non-Germinal Center, Determined by Immunohistochemistry on Tissue Microarray, Does Not Correlate with Outcome in Patients with relapsed and refractory DLBCL, *Blood*. 2005; 10:1182-1603.
  86. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebowl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*. 2005;105:54-60.

87. Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg D, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. *J Leukoc Biol.* 2004; 76:623-633.
88. MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B, Nimer SD. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. *Genes, Chromosomes. Cancer.* 2004;41:203-13.
89. Asakura K, Uchida H, Miyachi H, Kobayashi H, Yoshitaka M, Nimer SD, Takahashi H, Ikeda Y, Kizaki M. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 (MDR-1) gene expression. *Molecular Cancer Research.* 2004;2:339-347.
90. Gurrieri C, Nafa K, Merghoub T, Bernardi R, Capodieci P, Biondi A, Nimer SD, Douer D, Cordon-Cardo C, Gallagher R, Pandolfi PP. Mutations of the PML tumor suppressor gene in APL. *Blood.* 2004;103:2358-2362.
91. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. *Br J Haematol.* 2004;124:645-52.
92. Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Peterson FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, Van Biesen K, Horowitz MM. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. *Biol Blood Marrow Transplant.* 2004;10:116-27.
93. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Moskowitz CH. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. *Blood.* 2004;103:3684-88.
94. Scandura JM, Boccuni P, Massague J, Nimer SD. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. *Proc Natl Acad Sci USA.* 2004;101:15231-15236.
95. Garcia-Barros M, Lacorazza D, Petrie H, Haimovitz-Friedman A, Cardon-Cardo C, Nimer S, Fuks Z, Kolesnick R. Host acid sphingomyelinase regulates microvascular function not tumor immunity. *Cancer Res.* 2004;64:8285-91.
96. Hedvat C, Yao J, Sokolic R, Nimer SD. MEF is a Potent Activator of Interleukin-8 Expression in Hematopoietic Cells. *J. Biol. Chem.* 2004;279:6395-400.
97. Abrey L, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. *J Neurooncol.* 2003; 65:127-34.
98. Reece DE, Bredeson C, Peres WS, Jagannath S, Zhang MJ, Ballen KK, Eifenbein GJ, Freytes CO, Gale RP, Gertz MA, Gibson J, Giralt SA, Keating A, Kyle RA, Maharaj D, Marcellus D, McCarthy PL, Milone GA, Nimer SD, Pavlovsky S, To LB, Weisdorf DJ, Wiernik PH, Wingard JR, Vesole DH. Autologous stem cell transplantation in multiple myeloma patients <60 vs >=60 years of age. *BMT* 2003, 32: 1135-43.
99. Fujii S, Shimizu K, Klimek V, Geller M.D., Nimer SD, Dhodapkar M. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. *Br J Haematol.* 2003;122:617-22.
100. Mulloy J, Cammenga J, Berguido FJ, Wu K, Comenzo R, Jhanwar S, Moore M, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. *Blood.* 2003;102:4369-76.
101. Lauren E A, Moskowitz C, Mason W, Crump M, Stewart D, Forsyth P, Paleologos N, Correa D,

- Anderson N, Caron D, Zelenetz A, Nimer SD, DeAngelis L. Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: an Intent to Treat Analysis. *J Clin Oncol*. 2003;21:4151-6.
102. Kewalramani T, Nimer SD, Zelenetz AD, Mahotra S, Qin J, Yahalom J, Moskowitz, CH. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2003;32:673-679.
103. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Ely SA, Olshen AB, Osman K, Zhang Y, Kalakonda, N, Nimer, SD. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. *Br. J. Haem*. 2003;122:728-744.
104. Boccuni P, MacGrogan D, Scandura JM, Nimer SD. The human L(3)MBT polycomb group protein and TEL (ETV6) interact to repress transcription on specific promoters. *J. Biol. Chem*. 2003;278:15412-15420.
105. Wang WK, Tereshko V, Boccuni P, MacGrogan D, Nimer SD, Patel DJ. Polycomb group human lethal (3) malignant brain tumor repeats: propeller-like interdigitated architecture and drug/peptide-binding pockets. *Structure*. 2003;11:775-789.
106. Hamblin, P, Zelenetz, A, Kewalramani, T, Qin, T, Satagopan, J, Verbal, D, Noy, A, Portlock, C, Straus, D, Yahalom, Y, Nimer, SD, and Moskowitz, C, The age-adjusted international prognostic index predicts autologous stem cell transplant (ASCT) outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. *Blood*. 2003;102:1989-1996.
107. Zhou P, Zhang Y, Martinez C, Kalakonda N, Nimer SD, Comenzo RL. Melphalan mobilized blood stem cell components contain minimal clonotypic plasma cell contamination. *Blood*. 2003;102:477-479.
108. Fukushima T, Miyazaki Y, Tsushima H, Tsutsumi C, Taguchi J, Yoshida S, Kuriyama K, Scadden D, Nimer SD, Tomonaga M. The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. *Leukemia Research*. 2003;27:387-392.
109. Cigudosa JC, Calasanz MJ, Odero M.D., Sole F, Salido M, Arranz E, Martinez-Ramirez A, Urioste M, Alvarez S, Cervera J, Sanz MA, MacGrogan D, Nimer SD, Benitez J. De novo erythroleukemia chromosome features include multiple rearrangements with special involvement of chromosome 11 and 19. *Genes Chrom Cancer*. 2003;36:406-412.
110. Cammenga J, Mulloy J, Berguido F, MacGrogan D, Viale A, Nimer SD. Induction of C/EBP $\alpha$  activity alters gene expression and differentiation of human CD34+ cells. *Blood*. 2003;101:2206-2214.
111. Erter-Burns C, DeBlasio A, Zhou Y, Zhang J, Zon L, Nimer SD. Isolation and characterization of runxa and runxb, zebrafish members of the Runt family of transcriptional regulators. *Exp Hem*. 2002;30:1381-9.
112. Nimer SD, MacGrogan D, Jhanwar S, Alvarez S. Chromosome 19 abnormalities are commonly seen in AML, M7. *Blood*. 2002;100:3838-3839.
113. Hedvat C, Hedge A, Chaganti RSK, Chen B, Quin J, Filippa D, Nimer SD, Teruya-Feldstein J. Application of tissue microarray technology to the study of Non-Hodgkin's and Hodgkin's lymphoma. *Human Pathology*. 2002;33:968-974.
114. Lacorazza HD, Miyazaki Y, Decristofano A, Deblasio A, Hedvat CV, Mao S, Pandolfi PP, Nimer SD. The ETS Protein MEF Plays a Critical Role in Perforin Gene Expression and the Development of Natural Killer and NK-T Cells. *Immunity*. 2002;17:437-449 (cover article).
115. Mulloy JC, Cammenga J, MacKenzie KL, Moore MAS, Nimer SD. The AML1/ETO fusion protein promotes the expansion of human hematopoietic stem cells. *Blood* 2002; 99:15-23.

116. Hedvat CV, Jaffe ES, Qin J, Filippa DA, Cordon-Cardo C, Tosato G, Nimer SD, Teruya-Feldstein, J. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. *Mod Pathol.* 2001;12:1270-6.
117. Miyazaki Y, Mao S, Bocconi P, Zhang J, Erdjument-Bromage H, Tempst P, Kiyokawa H, Nimer SD. Cyclin A-dependent phosphorylation of the ETS-related protein, MEF, restricts its activity to the G1 phase of the cell cycle. *J Biol Chem.* 2001;276:40528-36.
118. Jurcic JG, Miller WH, Nimer SD, DeBlasio T, Scheinberg DA, Warrell RP, Miller WH. Prognostic Significance of Minimal Residual Disease Detection and PML/RAR- Isoform Type: Long-Term Follow-Up in Acute Promyelocytic Leukemia. *Blood.* 2001;98:2651-2656.
119. Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC. A recurrent abnormality of chromosome 19q in megakaryoblastic leukemia as revealed by molecular cytogenetic analysis. *Genes Chrom Cancer.* 2001;32:285-293.
120. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar S, Nimer SD. Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. *Oncogene.* 2001;20:4150-60.
121. Moskowitz CH, Nimer SD, Zelenetz A, Trippett T, Filippa D, Louie D, Gonzales M, Walits J, Coady-Lyons N, Frank R, Goy A, Hedrick E, Noy A, O'Brien J, Portlock C, Straus D, Yahalom J. A Two-step Comprehensive High-Dose Chemoradiotherapy Second-line Program for Refractory and Relapsed Hodgkin's Disease: Analysis by Intent to Treat and Development of a Prognostic Model. *Blood.* 2001;97:616-623.
122. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Greenberg PL. Report of an international working group to standardize response criteria for myelodysplastic syndromes. *Blood.* 2000;96:3671-3674.
123. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massagué J, Nimer SD. Inhibition of the TGF $\beta$ -1 signaling pathway by the AML1/ETO leukemia-associated fusion protein." *J. Biol. Chem.* 2000;275:40282-40287.
124. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Coady-Lyons N, Yahalom J, Nimer SD, Moskowitz CH. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. *Blood.* 2000;96:2399-404.
125. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2000;6:25-34.
126. Gajewski JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, von Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkinten D, Feig S, Territo M, Schiller G, Lebkowski J, Moseley AM, Lloyd K, von Hoeff M, Okarma T, and Champlin R. Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients. *Cytotherapy.* 1999 5:401-408.
127. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, Carboplatin and Etoposide, ICE, a highly effective cytoreduction and peripheral blood progenitor cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. *J Clin Oncology.* 1999;17:3776-3785.
128. Klampfer L, Zhang J, Nimer SD. GM-CSF promotes the survival of TF-1 cells through expression of BCL-2 and MCL-1. *Cytokine.* 1999;11:849-855.

129. Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD. Functional and physical interactions between AML1 proteins and an ETS protein, MEF: Implications for the pathogenesis of t(8;21) positive leukemias. *Mol Cell Biol.* 1999;19:3635-3644.
130. Klampfer L, Cammenga J, Wisniewski H-G, Nimer S. Sodium salicylate induces apoptosis of myeloid leukemia cell lines via caspase mediated cleavage of PARP and gelsolin. *Blood.* 1999;93:2386-2394.
131. Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ, O'Brien JP, Elkin N, Bertino JR, Zelenetz AD. The international prognostic index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate grade lymphoma. *Bone Marrow Transplant.* 1999;23:561-567.
132. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH-3T3 Cells and Activates AP-1. *Oncogene.* 1999;18:1701-1710.
133. Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. *Oncogene.* 1999;18:1015-1022.
134. Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VVVS, Massagué J. The type I TGF- $\beta$  receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. *Cancer Research.* 1998;58:2727-2732.
135. Paquette RL, Kuramoto K, Tran L, Sopher G, Nimer SD, Zeldis JB. Hepatitis C virus infection in acquired aplastic anemia. *Am J Hematol.* 1998;58:122-126.
136. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. *Clin Cancer Res.* 1998;4:311-316.
137. Shapiro F, Yao T-J, Moskowitz C, Reich L, Wuest DL, Heimfeld S, McNiece IK, Gabrilove J, Nimer S, Moore MAS. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. *Clin Cancer Res.* 1997;3:1571-1578.
138. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J. Recombinant methionyl human stem cell factor and Filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patient –Results of a phase I/II trial. *Blood.* 1997;89:3136-3147.
139. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. *Proc Natl. Acad Sci.* 1997;94:2609-2614.
140. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. *J Immunol.* 1997;158:2251-2258.
141. Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. *Bone Marrow Transplantation.* 1996;18:1057-1064.
142. Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer SD. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. *Oncogene.* 1996;13:1721-1729.
143. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. *Proc Natl. Acad Sci.* 1996;93:14059-14064.
144. Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious

- complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. *Bone Marrow Transplantation*. 1996;18:355-359.
145. Nimer S, Zhang J, Avraham H, Miyazaki Y. Transcriptional regulation of interleukin-3 expression in megakaryocytes. *Blood*. 1996;88:66-74.
  146. Nimer SD, Zhang W, Kwan K, Wang Y, Zhang J. Adjacent, cooperative elements form a strong, constitutive enhancer in the human granulocyte-macrophage colony-stimulating factor gene. *Blood*. 1996;87:3694-3703.
  147. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. *Oncogene*. 1995;11:2667-2674.
  148. Zhang W, Zhang J, Kornuc M, Kwan K, Frank R, Nimer SD. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. *Mol Cell Biol*. 1995 15:6055-6063.
  149. Paquette RL, Minosa MR, Verma MC, Nimer SD, Koeffler HP. An interferon- $\gamma$  activation sequence mediates the transcriptional regulation of the IgG Fc receptor type IC gene by interferon- $\gamma$ . *Mol. Immunol*. 1995;32:841-851.
  150. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping. *Gene Expression*. 1995;4:281-299.
  151. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. A Phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. *Blood*. 1995;85:3066-3076.
  152. Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SD. Long-term outcome of aplastic anemia in adults treated with anti-thymocyte globulin: Comparison with bone marrow transplantation. *Blood*. 1995;85:283-90.
  153. Nimer SD, Leung DHY, Wolin MJ, Golde DW. Serum stem cell factor levels in patients with severe aplastic anemia. *Intl. J Hematol*. 1994;60:185-189.
  154. Fraser JK, Tran S, Nimer SD, Gasson JC. Characterization of nuclear factors which bind to a critical positive regulatory element of the human granulocyte-macrophage colony-stimulating factor promoter. *Blood*. 1994;84:2523-2530.
  155. Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski J. Treatment of advanced acute leukemia with allogeneic bone marrow transplantation from unrelated donors. *Br J Haematol*. 1994;88:72-78.
  156. Schiller G, Nimer S, Vescio R, Lieb G, Lee M, Gajewski J, Territo M, Berenson J. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. *Bone Marrow Transplantation*. 1994;14:131-136.
  157. Nimer SD, Paquette RL, Ireland P, Resta D, Young D, Golde DW. A Phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. *Exp. Hem*. 1994;22:875-880.
  158. Chap L, Nimer SD. Chronic myelogenous leukemia following repeated radiation therapy for histiocytosis X. *Leuk & Lymph*. 1994;12:315-316.
  159. Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. *Blood*. 1994;84:923-927.
  160. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert TA, Champlin RE. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. *Transplantation*. 1994;57:82-87.
  161. Fraser JK, Guerra JJ, Nguyen CY, Indes JE, Gasson JC, Nimer SD. Characterization of a cell-type-restricted negative regulatory activity of the human granulocyte-macrophage colony-stimulating factor gene. *Mol Cell Biol*. 1994;14:2213-2221.
  162. Chap L, Schiller G, Nimer SD. The use of recombinant GM-CSF following allogeneic bone

- marrow transplantation for aplastic anemia. *Bone Marrow Transplantation*. 1993;12:173-175.
163. Wolin M, Kornuc M, Hong C, Shin SK, Lee F, Lau R, Nimer S. Differential effect of HTLV infection and HTLV Tax on interleukin 3 expression. *Oncogene*. 1993;8:1905-1911.
164. Schiller G, Nimer S, Gajewski J, Lee M, Ho W, Territo M, Champlin R. Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: Results of a randomized, controlled study. *Leuk & Lymph*. 1993;11:69-77.
165. Schiller G, Lee M, Territo M, Gajewski J, Nimer S. Phase II study of etoposide, ifosfamide and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. *Am J Hematol*. 1993 43:195-199.
166. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. *Blood*. 1992; 80:2977-2982.
167. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin R. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia. *Br J Haematol*. 1992;81:170-177.
168. Sakamoto KM, Nimer SD, Rosenblatt JD, Gasson JC. HTLV-I and HTLV-II tax trans-activate the human EGR-1 promoter through different cis-acting sequences. *Oncogene*. 1992;7:2125-2130.
169. Sawyers CL, Golde DW, Quan S, Nimer SD. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis and eosinophilia. *Cancer*. 1992;62:1342-1346.
170. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. *J Clin Oncol*. 1992;10:41-46.
171. Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T. Retention of graft-versus-leukemia using selective depletion of CD8-positive T-lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. *Transplant Proceed*. 1991;23:1695-1696.
172. Schiller GJ, Nimer SD, Gajewski JL, Golde DW. Abdominal Presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. *Bone Marrow Transplantation*. 1991;7:489-491.
173. Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin R. In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: Possible mechanisms of action of antithymocyte globulin. *Blood*. 1991;78:163-168.
174. Nimer S. Tax responsiveness of the GM-CSF promoter is mediated by mitogen inducible sequences other than NF-KB. *The New Biologist*. 1991;3:997-1004.
175. Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W. Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with high-dose cytarabine and daunorubicin consolidation treatment. *J Clin Oncol*. 1990;8:1199-1206.
176. Nimer SD, Milewicz AL, Champlin RE, Busuttill RW. Successful treatment of hepatic veno-occlusive disease in a bone marrow transplant patient with orthotopic liver transplantation. *Transplantation*. 1990;49:819-821.
177. Naeim F, Champlin R, Nimer S. Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. *Hematologic Pathology*. 1990;4:79-85.
178. Champlin RE, Nimer SD, Oette D, Golde DW. Effects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis. *Progress in Clin and Biol Research*. 1990;338:143-150.
179. Champlin RE, Ho WG, Nimer SD, Gajewski JG, Selch M, Burnison M, Holley G, Yam P, Petz L, Winston DJ, Feig SA. Bone marrow transplantation for severe aplastic anemia: Effect of a

- preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and post transplant cyclosporine-methotrexate therapy. *Transplantation*. 1990;49:720-724.
180. Nimer S, Fraser J, Richards J, Lynch M, Gasson J. The repeated sequence CATT (A/T) is required for granulocyte-macrophage colony-stimulating factor promoter activity. *Mol Cell Biol*. 1990;10:6084-6088.
  181. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RE. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. *J Clin Oncol* 1989; 7:1637-1645.
  182. Nimer SD, Gates MJ, Koeffler HP, Gasson JC. Multiple mechanisms control the expression of granulocyte-macrophage colony-stimulating factor by human fibroblasts. *J Immunol*. 1989;143:2374-2377.
  183. Nimer SD, Gasson JC, Hu K, Smalberg I, Williams JL, Chen ISY, Rosenblatt JD. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. *Oncogene*. 1989;4:671-676.
  184. Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DW. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. *Blood*. 1989;73:694-699.
  185. Nimer SD, Champlin RE, Golde DW. Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. *JAMA*. 1988;260:3297-3300.
  186. Nimer SD, Morita EA, Martis MJ, Wachsman W, Gasson JC. Characterization of the human granulocyte-macrophage colony-stimulating factor promoter region by genetic analysis: Correlation with DNase I footprinting. *Mol Cell Biol*. 1988;8:1979-1984.
  187. Chan JY, Slamon DJ, Nimer SD, Golde DW, Gasson JC. Regulation of expression of human granulocyte-macrophage colony-stimulating factor. *Proc Natl. Acad Sci USA*. 1986;83:8669-8673.
  188. Rossi EC, Nimer S, Louis G. Inhibition of platelet aggregation by 5-nitro-2 furaldehyde diacetate with observations on structure-activity relationships. *J Lab Clin Med*. 1976;87:703-709.

Other works, publications and abstracts:

Reviews, Editorials, Letters to the Editor:

1. Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. *Leukemia*. 2014 Mar 10. doi : 10.1038/leu.2014.94. [Epub ahead of print].
2. Greenblatt SM, H.Joachim Deeg, Nimer SD. MDS Stem Cell Biology. In: *Myelodysplastic Syndromes, Second Edition*, ed. Springer. 2013 4:73-84
3. Liu Y, Yu H, Nimer SD. PI3K-Akt pathway regulates polycomb group protein and stem cell maintenance. *Cell Cycle*. 2013;12:199-200.
4. Vu LP, Luciani L, Nimer SD. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. *Int J Hematol*. 2013;97:198-209.
5. Asai T, Liu Y, Nimer, SD. Necdin, a p53 target gene, in normal and cancer stem cells. *Oncotarget*. 2013, 4:806-7. Epub Apr 29.
6. Vu LP, Luciani L, Nimer SD. Histone-modifying enzymes: their roles in the pathogenesis of acute leukemia and their therapeutic potential. *Int J Hematol*. 2013;97:198-209.
7. Liu Y, Yu H, Nimer SD. PI3K-Akt pathway regulates polycomb group protein and stem cell maintenance. *Cell Cycle*. 2013;12:199-200. doi: 10.4161/cc.23379. Epub 2012 Jan 15.
8. Hatlen MA, Wang L, Nimer SD, AML1-ETO driven acute leukemia: Insights into pathogenesis and potential therapeutic approaches. *Front Med*. Sep;6:248-62. Epub 2012.
9. Nimer SD. An update on the molecular pathogenesis of myelodysplastic syndromes. *Biol Blood*



- Marrow Transplant. 2011;17:S11-4.
10. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. Myelodysplastic syndromes. *P.J Natl Compr Canc Netw*. 2011;9:30-56.
  11. Asai T, Liu Y, Bae N, & Nimer SD. The p53 Tumor Suppressor protein Regulates Hematopoietic Stem Cell Fate. *Journal Of Cellular Physiology*. 2011;226:2215-21. doi: 10.1002/jcp.22561.
  12. Sashida G, Bazzoli E, Menendez S, Liu Y, Nimer SD. The oncogenic role of the ETS transcription factors MEF and ERG. *Cell Cycle*. 2010;9:3457-9.
  13. Liu Y, Takashi A & Nimer SD. Myelodysplasia: battle in the bone marrow. *Nature Medicine*. 2010;16:30-2.
  14. Liu Y, Hoya-Arias R & Nimer SD. The role of p53 in limiting somatic cell reprogramming. *Cell Research*. 2009;19:1227-8.
  15. Landau H & Nimer SD. Evaluation and Treatment of Leukemia and Myelodysplasia. In: *Cancer Rehabilitation: Principles and Practice*, ed. Michael D. Stubblefield and Michael W. O'Dell. 2009;19:253-266.
  16. Liu Y, Elf S, Asai T, Miyata Y, Sashida G, Huang G, Di Giandomenico, Koff, Nimer SD. The p53 tumor suppressor protein is a critical regulator of hematopoietic cell behavior. *Cell Cycle* 2009; 8:3120-4.
  17. Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, & Nimer SD. Post- translational modifications of Runx1 regulate its activity in the cell. *Blood Cells, Molecules and Diseases*. 2009 43:30-4
  18. Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. *Cancer Control*. 2008;Suppl:4-13
  19. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, Decastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P. Myelodysplastic syndromes. *J Natl Compr Canc Netw*. 2008;6:902-26.
  20. Nimer SD. MDS: A Stem Cell Disorder- But What Exactly is Wrong with the Primitive Hematopoietic Cells in This Disease? *Hematology Am Soc Hematol Educ Program*. 2008;43-51
  21. Nimer SD. Molecular and Genetic Abnormalities in MDS. In: *Myelodysplastic Syndromes: State of the Art*, ed. E-Hellstrom-Lindberg. 2008 2:37-56
  22. Nimer SD. Myelodysplastic Syndromes (invited review article). *Blood* 2008; 111:4841-51
  23. Nimer SD. Is it important to decipher the heterogeneity of "normal karyotype AML"? In: *Best Practice & Research Clinical Haematology*. 2008;21:43-52
  24. Klimek V, Nimer S. Treatment Approach to Early Myelodysplastic Syndromes. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. *Clinical Malignant Hematology*. New York: McGraw – Hill; 2007.
  25. Gu T-L, Popova L, Reeves C, Nardone J, MacNeill J, Rush J, Nimer SD, Polakiewicz RD. Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia. *Leukemia* 2007 (letter);21:563-6.
  26. Nimer SD. Many plusses come from studying 5q- Myelodysplastic Syndrome. *Clinical Leukemia*. 2006,1:34-5.
  27. Nimer SD. Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q. *J. Clin. Onc*. 2006;134:202-7.
  28. Greenberg PL, Baer MR, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Devetten MP, Emanuel PD, Erba HP, Estey E, Foran J, Gore SD, Millenson M, Navarro WH, Nimer SD, O'Donnell MR, Saba HI, Spiers K, Stone RM, Tallman MS. Myelodysplastic syndromes clinical

- practice guidelines in oncology. *J Natl Compr Canc Netw*. 2006;4:58-77.
29. Nimer SD, Janjigian Y. A role for WNT signaling in adult T-cell leukemia? *Leukemia Research*. 2005 (editorial);29:475-476.
  30. Nimer SD, Moore MAS. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. *Oncogene*. 2004;23 4249-4254.
  31. Nimer SD, Blood and RUNX1: got to have it, really need it (commentary) *Blood*. 2004;104:3420-3421
  32. Lacorazza D, Nimer, SD. The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesis. *Blood Cells Mol Dis*. 2003;31:342-50.
  33. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. *Ann Oncol*. 2003;14 (supp 1):i5-i10.
  34. Nimer SD. Review of Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. *The American Journal of Oncology Review*. 2002 (Commentary). 1:2-3.
  35. Nimer SD. Autotransplants for Hodgkin's Disease; Are the Issues Settled? *The American Journal of Oncology Review* 2002 (Commentary). 1:179-80.
  36. Alvarez S, MacGrogan D, Rodriguez-Perales S, Martinez-Ramirez A, Urioste M, Benitez J, Nimer S, Cigudosa JC. Cytogenetic characterization reveals that the SAM-1 erythroid cell line is derived from K-562 cells. *Blood* 2002 (letter). 100:3435-3436.
  37. Nimer SD, Macgrogan D, Jhanwar S, Alvarez S, Chromosome 19 Abnormalities are Commonly seen in AML, M7. *Blood*. 2002;100:3838-9
  38. Cammenga J, Nimer SD. Mutations in human cancers: how close should we look? *Leuk Res*. 2002;5 459-460.
  39. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. *Oncogene*. 2002;21:3422-3444.
  40. Nimer SD. Understanding Cellular Networks in the Year 2001. *Blood*. 2001;97:1905.
  41. Frank RC, Nimer SD. t(8;21) AML and the AML1/ETO fusion gene: From clinical syndrome to paradigm for the molecular basis of acute leukemia. In: Ravid K, Licht J, ed. *Transcription factors: normal and malignant development of blood cells*; p. 409-424 John Wiley & Sons 2001.
  42. Cheson BD, Bennett JM, Kantarjian H., Schiffer CA, Nimer SD, Löwenberg B, Stone RM, Mittelman M, Sanz GF, Wijermans PW, and Greenberg PL. Response: Myelodysplastic syndromes standardized response criteria: further definition. *Blood* (letter). 2001;1985-1986.
  43. Heaney ML, Nimer SD. Review of the cox hematotoxicity model. *J Toxicol Environ Health*. 2000;61:539-41.
  44. Nimer SD. Transcription Factors Active in Megakaryocyte Development. In: Zon LI, ed. *Developmental Biology of Hematopoiesis*. Oxford Univ. Press. 2001, p. 443-449.
  45. Jakubowiak A, Cammenga J, Sokolic R, Alvarez S, Jackson G, Nimer SD. *Molecular Biology of Leukemia*. *Current Oncology Reports*. 2:123-131, 2000.
  46. Moskowitz CH, Nimer SD. Autologous Transplantation for Hodgkin's Disease: Who Benefits? In: Bolwell BJ, ed. *Current Controversies in Bone Marrow/Stem Cell Transplantation*. Humana Press 2000: 137-145.
  47. Frank RC, Nimer SD. Transcription Factors and Malignancy. In: Kurzrock R, Talpaz M, eds. *Molecular Biology in Cancer Medicine*. 2nd ed. London: Martin Dunitz Publ. 1999 147-159.
  48. Nimer SD. Essential Thrombocythemia - Another "Heterogeneous Disease Better Understood?" *Blood* 1999; 93:415-416.
  49. Maslak P, Nimer SD. The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. *Sem. in Hematology*. 1998;35:253-260.
  50. Nimer, SD. Platelet stimulating agents - off the launching pad. *News & Views*. *Nature Medicine*.

1997;3:154-155.

51. Zhang W, Look AT, Inaba T, Nimer SD. IL3BP1, a transcription factor with dual function. In: Abraham NG et al., eds. *Molecular Biology of Hematopoiesis 5*, NY: Plenum Press, 1996:397-402.
52. Nimer SD, Childs BH. Aplastic Anemia. In: Rakel R, ed. *Conn's Current Therapy*. W.B. Saunders Co. 1996:333-336.
53. Nimer SD, Pavlick AC. Hematopoietic and Lymphoreticular Systems. In: Goldberg, JS, ed. *USMLE Step 1 Review: The Study Guide*. Thousand Oaks, CA: Sage Publications, 1996:295-308.
54. Nimer SD, Zelenetz A, Portlock C. Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma [letter]. *N Engl J Med* 1995;333:728-729.
55. Nimer SD. The role of cytokines in the pathogenesis and treatment of aplastic anemia and myelodysplastic syndromes. In: Gluckman E, Coulombel L, eds. *Ontogeny of Hematopoiesis. Aplastic Anemia*. Paris: John Libbey Eurotext Ltd, 1995;235:353-359.
56. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho, W, Feig S, Selch M, Isacescu V, Reichert TA, Champlin RE. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. In: Simone, JV, ed. *The Year Book of Oncology*. St. Louis, MO: Mosby, Inc., 1995:474-476.
57. Nimer S, Uchida H. Regulation of granulocyte-macrophage colony-stimulating factor and interleukin 3 expression. *Stem Cells* 1995;13:324-335.
58. Nimer SD. Transcription Factors and Malignancy. In: Kurzrock R, Talpaz M, eds. *Molecular Biology in Clinical Oncology and Hematology*. London: Martin Dunitz Publ. 1995:113-128.
59. Nimer SD, Golde DW. Molecular, cell and clinical biology of the phagocyte. In: Handin RI, Lux SE, Stossel TP, eds. *Blood: Principles and Practice of Hematology*. J.B. Lippincott Co, 1995:513-541.
60. Nimer SD, Pavlick A. "Hematology and Oncology" section. In: Goldberg, JS, ed. *The Instant Exam Review for the USMLE Step 3*. Norwalk, CN: Appleton and Lange, 1994:97-114.
61. Naeim F, Nimer S. Bone marrow structure and function. In: Naeim F, ed. *Pathology of the Bone Marrow*. NY: Igaku Shoin, 1992:1-31.
62. Nimer SD. Colony-stimulating factors: Biology and therapy. In: Peterson DE, Greenspan D, Squier CA, eds. *Oral Infections in the Immunocompromised Host*. International Association for Dental Research Symposium, April 19, 1991, Acapulco, Mexico. *J Oral Pathol Med*. 1992;21:193-198.
63. Nimer SD. Hematopoietic growth factors. In: Rose NR, de Macario EC, Fahey JL, Friedman H, Renn GM, eds. *Manual of Clinical Laboratory Immunology*, Fourth edition. Washington, D.C.: American Society for Microbiology. 1992:244-247.
64. Nimer SD. The use of colony-stimulating factors in primary hematologic disorders. *Cancer* 1992; 70(Suppl):921-927.
65. Nichols J, Nimer SD. Transcription factors, translocations, and leukemia. *Blood*. 1992;80:2953-2963.
66. Nimer SD. Molecular biology and hematology of erythropoietin. In: Nissenson AR, moderator. *Recombinant human erythropoietin and renal anemia: Molecular biology, clinical efficacy and nervous system effects*. *Ann Intern Med*. 1991;114:402-416.
67. Nimer SD. Book Review: *Blood Cell Growth Factors: Their Biology and Clinical Applications*. *Cancer Cells*. 1990;2:330-331.
68. Nimer SD, Champlin RE. Therapeutic use of hematopoietic growth factors in bone marrow transplantation. In: Champlin RE, ed. *Bone Marrow Transplantation*. Norwell, MA: Kluwer Academic Publishers. 1990:141-164.

69. Gasson JC, Fraser JK, Nimer SD. Human granulocyte-macrophage colony-stimulating factor (GM-CSF): regulation of expression. In: Spivak J, Drohan W, Dooley D, eds. Proceedings of the American Red Cross Annual Symposium on Hematopoietic Growth Factors in Transfusion Medicine. NY: Alan R. Liss. 1990:27-41.
70. Black AC, Nimer SD, Chen ISY, Rosenblatt JD. The effects of tax and rex protein of HTLV-I and -II on viral and cellular gene regulation. In: Groopman J, Chen ISY, Essex M, Weiss R, eds. Early Human Retroviruses. UCLA Symposia on Molecular and Cellular Biology. NY: Alan R. Liss, Inc., 1990, 119:33-47.
71. Nimer SD, Gasson JC, DiPersio JF. Expression and target cell specificity of human granulocyte-macrophage colony-stimulating factor. In: Cruse JM, Lewis RE, eds. The Year in Immunology, 1986-87, Vol. 3, Basel, S: Karger, 1988:144-151.10:6084-6088.
72. Nimer SD, Golde DW. The 5q -Abnormality. Blood 1987; 70:1705-1712.
73. Nimer SD, Gasson JC. Identification of regulatory sequences in the 5' flanking region of the human GM-CSF gene. In: Gale RP, Golde DW, eds. Recent Advances in Leukemia and Lymphoma, UCLA Symposia on Molecular and Cellular Biology, Vol. 61, NY: Alan R. Liss, Inc., 1987:229-238.
74. Rossi EC, Nimer S, Louis G. The effect of certain alkyl-substituted analogues of nitrofurantoin upon platelet aggregation. In: Ulutin ON, ed. Platelets: Recent Advances in Basic Research and Clinical Aspects. Amsterdam: Excerpta Medica/American Elsevier, 1975:324-328.